

( (S (NP-SBJ Cetus Corp.)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the government)
                          (PP of
                              (NP Spain)))
                  (VP approved
                      (NP (NP the marketing)
                          (PP of
                              (NP (NP its Proleukin interleukin-2 drug)
                                  (SBAR (WHNP-1 0)
					(S (NP-SBJ *T*-1) 
					   (VP to
					       (VP treat
						   (NP kidney cancer))))))))))))
     .))
( (S (NP-SBJ The biotechnology concern)
     (VP said
         (SBAR (SBAR 0
                     (S (NP-SBJ Spanish authorities)
                        (VP must
                            (ADVP still)
                            (VP clear
                                (NP (NP the price)
                                    (PP for
                                        (NP the treatment)))))))
               , but
               (SBAR that
                     (S (NP-SBJ-1 it)
                        (VP expects
                            (S (NP-SBJ *-1)
                               (VP to
                                   (VP receive
                                       (NP such approval)
                                       (PP-TMP by
					       (NP year end))))))))))
     .))
( (S (NP-SBJ (NP Four other countries)
             (PP-LOC in
		     (NP Europe)))
     (VP have
         (VP approved
             (NP Proleukin)
             (PP-TMP in
		     (NP recent months))))
     .))
( (S (NP-SBJ-1 Cetus)
     (VP is
         (ADVP-TMP currently)
         (VP trying
             (S (NP-SBJ *-1)
                (VP to
                    (VP obtain
                        (NP (NP federal regulatory clearance)
                            (PP for
                                (NP U.S. distribution))))))))
     .))
